UWM Holdings Corporation

UWM Holdings Corporation (NYSE: UWMC) is a residential mortgage loan originator, seller, and servicer. UWMC generates revenue from three sources: loan production, loan servicing, and interest income.

Key Highlights

• The company reported a 41.65% decline in total revenues to USD 484.65 million in Q2FY21 (ended June 30, 2021) compared to USD 830.65 million in Q2FY20.
• Net income for the quarter was USD 138.71 million vs. USD 539.49 million reported in Q2FY20.
• Due to high operational expenditures such as salaries, commissions, benefits, and marketing, travel, and entertainment, UWMC's operating margin fell to 61.4% in Q2FY21, compared to 78.9% in Q1FY21.
• Post Q2FY21 end, it repurchased an additional 1.5 million common shares for a total consideration of USD 11.5 million under its share repurchase plan.
• Stock is currently trading below its crucial short-term (50-day) and long-term (200-day) SMA support levels, indicating a bearish trend.
• Stock is leaning towards the lower band of the 52-week range of USD 6.25 to USD 14.38.
• UWMC stock price has declined 27.21% and 31.89% in the past nine and twelve months, respectively.

Technical Price Chart (as of September 02, 2021). Analysis by Kalkine

Conclusion: Considering the volatility in the interest rates, macroeconomic conditions, pressure on profit margins, uncertain outlook, and technical indicators, we recommend an "Avoid" rating on the stock at the closing price of USD 7.41, up 0.14% as of September 02, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Sesen Bio, Inc.

Sesen Bio, Inc. (NASDAQ: SESN) is a late-stage clinical company engaged in developing next-gen antibody-drug conjugate therapies for cancer treatment using its Targeted Protein Therapeutics platform.

Key Highlights

• SESN has yet to commercialize any therapeutic candidate and reported USD 2.23 million under license and related income in Q2FY21 (ended June 30, 2021).
• It exited the quarter with a cash balance of USD 151.04 million and no outstanding debt.
• On August 13, 2021, the US Food and Drug Administration (FDA) determined that the Biologics License Application (BLA) for Vicineum in its current form is ineligible for approval and made recommendations relating to a recent pre-approval inspection and product quality.
• At present, SESN has against it a class-action lawsuit claiming that it neglected to disclose to investors that the Vicineum clinical trial had over 2,000 protocol breaches and submitted corrupted data under the BLA.
• Stock is currently trading far below its crucial short-term as well as long-term 50-day and 200-day SMA support levels.
• Stock is leaning towards the lower-band of the 52-week range of USD 0.70 to USD 6.04.
• SESN's stock price fell 73.18% and 71.08% in the past one and three months, respectively.

Technical Price Chart (as of September 02, 2021). Analysis by Kalkine

Conclusion: Considering the absence of revenues, uncertain outlook, recent lawsuit, and technical indicators, we recommend an "Avoid" rating on the stock at the closing price of USD 1.07, up 8.40% as of September 02, 2021.

*The reference data in this report has been partly sourced from REFINITIV.

Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.

Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.

You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.

Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.